511 related articles for article (PubMed ID: 27890785)
21. Melanocytic nevi and tumor progression: perspectives concerning histomorphology, melanoma risk and molecular genetics.
Barnhill RL
Dermatology; 1993; 187(2):86-90. PubMed ID: 8358111
[TBL] [Abstract][Full Text] [Related]
22. Melanocytic lesions in a private pathology practice. Comparison of histologic features in different tumor types with particular reference to dysplastic nevi.
Hastrup N; Hou-Jensen K
APMIS; 1993 Nov; 101(11):845-50. PubMed ID: 8286092
[TBL] [Abstract][Full Text] [Related]
23. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
[TBL] [Abstract][Full Text] [Related]
24. Dysplastic melanocytic nevus: Are molecular findings the key to the diagnosis?
Xavier-Junior JCC; Ocanha-Xavier JP
Ann Diagn Pathol; 2022 Oct; 60():152006. PubMed ID: 35839551
[TBL] [Abstract][Full Text] [Related]
25. Dysplastic nevus part II: Dysplastic nevi: Molecular/genetic profiles and management.
Spaccarelli N; Drozdowski R; Peters MS; Grant-Kels JM
J Am Acad Dermatol; 2023 Jan; 88(1):13-20. PubMed ID: 36252690
[TBL] [Abstract][Full Text] [Related]
26. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
Singh RS; Diwan AH; Zhang PS; Prieto VG
J Cutan Pathol; 2007 Mar; 34(3):220-5. PubMed ID: 17302605
[TBL] [Abstract][Full Text] [Related]
27. Dysplastic nevi and other risk markers for melanoma.
Seykora J; Elder D
Semin Oncol; 1996 Dec; 23(6):682-7. PubMed ID: 8970587
[TBL] [Abstract][Full Text] [Related]
28. Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer.
Bastian BC
Oncogene; 2003 May; 22(20):3081-6. PubMed ID: 12789284
[TBL] [Abstract][Full Text] [Related]
29. C-kit expression of melanocytic neoplasm and association with clinicopathological parameters and anatomic locations in Chinese people.
Lin YC; Chang YM; Ho JY; Lin HC; Tsai YM; Chiang CP; Wang WM; Gao HW
Am J Dermatopathol; 2013 Jul; 35(5):569-75. PubMed ID: 23221472
[TBL] [Abstract][Full Text] [Related]
30. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J
J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117
[TBL] [Abstract][Full Text] [Related]
31. Molecular aspects of melanocytic dysplastic nevi.
Hussein MR; Wood GS
J Mol Diagn; 2002 May; 4(2):71-80. PubMed ID: 11986397
[TBL] [Abstract][Full Text] [Related]
32. A distinctive melanocytic lesion associated with melanoma-prone dysplastic naevus syndrome: the hybrid naevus.
Schubert C; Parwaresch R; Rudolph P
Virchows Arch; 2001 Feb; 438(2):166-72. PubMed ID: 11253119
[TBL] [Abstract][Full Text] [Related]
33. A meta-analysis of nevus-associated melanoma: Prevalence and practical implications.
Pampena R; Kyrgidis A; Lallas A; Moscarella E; Argenziano G; Longo C
J Am Acad Dermatol; 2017 Nov; 77(5):938-945.e4. PubMed ID: 28864306
[TBL] [Abstract][Full Text] [Related]
34. Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report.
Mordoh A; Triviño Pardo JC; Carri I; Barrio MM; Mordoh J; Aris M
BMC Med Genomics; 2023 Jan; 16(1):1. PubMed ID: 36604730
[TBL] [Abstract][Full Text] [Related]
35. Dysplastic Nevi: Morphology and Molecular and the Controversies In-between.
Wiedemeyer K; Hartschuh W; Brenn T
Surg Pathol Clin; 2021 Jun; 14(2):341-357. PubMed ID: 34023110
[TBL] [Abstract][Full Text] [Related]
36. Trajectories of premalignancy during the journey from melanocyte to melanoma.
Colebatch AJ; Scolyer RA
Pathology; 2018 Jan; 50(1):16-23. PubMed ID: 29132722
[TBL] [Abstract][Full Text] [Related]
37. Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.
Gao L; van den Hurk K; Moerkerk PTM; Goeman JJ; Beck S; Gruis NA; van den Oord JJ; Winnepenninckx VJ; van Engeland M; van Doorn R
J Invest Dermatol; 2014 Dec; 134(12):2957-2966. PubMed ID: 24999589
[TBL] [Abstract][Full Text] [Related]
38. The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi.
Elder DE; Clark WH; Elenitsas R; Guerry D; Halpern AC
Semin Diagn Pathol; 1993 Feb; 10(1):18-35. PubMed ID: 8506414
[TBL] [Abstract][Full Text] [Related]
39. Correlation of clinical pigmentary characteristics with histopathologically-confirmed dysplastic nevi in nonfamilial melanoma patients. Studies of melanocytic nevi IX.
Roush GC; Barnhill RL
Br J Cancer; 1991 Nov; 64(5):943-7. PubMed ID: 1931621
[TBL] [Abstract][Full Text] [Related]
40. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions.
Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR
Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
